$NKTR
Nektar Therapeutics Stock $nktr

$nktr Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-Q Financial Statement

#000090670920000017 Filed on November 06, 2020

Income Statement

Concept	2020 Q4	2020 Q3	2019 Q3
Revenue	$23.46M	$30.03M	$29.22M
YoY Change	-30.71%	2.79%	5.24%
Cost Of Revenue	$4.323M	$5.570M	$4.927M
YoY Change	-27.82%	13.05%	3.01%
Gross Profit	$19.14M	$24.46M	$24.29M
YoY Change	-31.33%	0.71%	5.71%
Gross Profit Margin	81.57%	81.45%	83.14%
Selling, General & Admin	$27.10M	$27.00M	$24.00M
YoY Change	0.0%	12.5%	28.34%
% of Gross Profit	141.6%	110.37%	98.8%
Research & Development	$102.7M	$100.5M	$99.05M
YoY Change	-6.93%	1.5%	-3.74%
% of Gross Profit	536.73%	410.95%	407.76%
Depreciation & Amortization	$3.300M	$3.200M	$3.500M
YoY Change	-8.33%	-8.57%	29.63%
% of Gross Profit	17.24%	13.08%	14.41%
Operating Expenses	$102.7M	$100.5M	$99.05M
YoY Change	-6.93%	1.5%	-3.74%
Operating Profit	-$110.7M	-$103.1M	-$98.74M
YoY Change	0.99%	4.36%	0.11%
Interest Expense	-$6.400M	$0.00	$5.425M
YoY Change	190.91%	-100.0%	-0.31%
% of Operating Profit
Other Income/Expense, Net		-$5.515M	$254.0K
YoY Change		-2271.26%	-84.04%
Pretax Income	-$117.1M	-$108.6M	-$98.49M
YoY Change	4.65%	10.23%	1.49%
Income Tax	$100.0K	$21.00K	$99.00K
% Of Pretax Income
Net Earnings	-$117.2M	-$108.6M	-$98.59M
YoY Change	4.49%	10.14%	2.54%
Net Earnings / Revenue	-499.54%	-361.56%	-337.41%
Basic Earnings Per Share	-$0.65	-$0.61	-$0.56
Diluted Earnings Per Share	-$0.65	-$0.61	-$0.56
COMMON SHARES
Basic Shares Outstanding	179.4M shares	179.1M shares	175.4M shares
Diluted Shares Outstanding		179.1M shares	175.4M shares

Balance Sheet

Concept	2020 Q4	2020 Q3	2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.062B	$956.0M	$1.496B
YoY Change	-19.85%	-36.08%	5.3%
Cash & Equivalents	$199.0M	$55.84M	$81.22M
Short-Term Investments	$862.9M	$900.2M	$1.414B
Other Short-Term Assets	$21.93M	$21.55M	$15.21M
YoY Change	42.51%	41.66%	21.31%
Inventory	$15.29M	$12.89M	$13.72M
Prepaid Expenses
Receivables	$38.89M	$42.93M	$41.21M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.138B	$1.044B	$1.579B
YoY Change	-19.95%	-33.88%	4.89%
LONG-TERM ASSETS
Property, Plant & Equipment	$59.66M	$60.19M	$64.61M
YoY Change	-9.14%	-6.85%	43.91%
Goodwill	$76.50M	$76.50M	$76.50M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$136.7M	$197.7M	$231.1M
YoY Change	-51.02%	-14.45%	-62.67%
Other Assets	$1.461M	$1.420M	$2.385M
YoY Change	324.71%	-40.46%	-29.85%
Total Long-Term Assets	$400.8M	$464.8M	$509.5M
YoY Change	-27.9%	-8.77%	-31.52%
TOTAL ASSETS
Total Short-Term Assets	$1.138B	$1.044B	$1.579B
Total Long-Term Assets	$400.8M	$464.8M	$509.5M
Total Assets	$1.539B	$1.509B	$2.088B
YoY Change	-22.18%	-27.76%	-7.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$22.14M	$15.48M	$21.96M
YoY Change	15.1%	-29.5%	192.84%
Accrued Expenses	$93.50M	$110.5M	$95.00M
YoY Change	17.61%	16.32%	21.33%
Deferred Revenue	$91.00K	$507.0K	$8.400M
YoY Change	-98.35%	-93.96%	-46.41%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00
YoY Change	-100.0%
Total Short-Term Liabilities	$115.8M	$126.5M	$125.4M
YoY Change	-67.28%	0.92%	15.96%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$248.3M
YoY Change		-100.0%	0.73%
Other Long-Term Liabilities	$8.980M	$3.291M	$643.0K
YoY Change	1069.27%	411.82%	-99.38%
Total Long-Term Liabilities	$8.980M	$3.291M	$643.0K
YoY Change	1069.27%	411.82%	-99.82%
TOTAL LIABILITIES
Total Short-Term Liabilities	$115.8M	$126.5M	$125.4M
Total Long-Term Liabilities	$8.980M	$3.291M	$643.0K
Total Liabilities	$461.5M	$337.7M	$599.6M
YoY Change	-19.32%	-43.68%	30.63%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.309B	-$2.192B	-$1.751B
YoY Change	23.83%	25.16%
Common Stock	$3.389B	$3.364B	$3.241B
YoY Change	3.6%	3.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.077B	$1.171B	$1.489B
YoY Change
Total Liabilities & Shareholders Equity	$1.539B	$1.509B	$2.088B
YoY Change	-22.18%	-27.76%	-7.15%

Cashflow Statement

Concept	2020 Q4	2020 Q3	2019 Q3
OPERATING ACTIVITIES
Net Income	-$117.2M	-$108.6M	-$98.59M
YoY Change	4.49%	10.14%	2.54%
Depreciation, Depletion And Amortization	$3.300M	$3.200M	$3.500M
YoY Change	-8.33%	-8.57%	29.63%
Cash From Operating Activities	-$98.60M	-$52.70M	-$68.70M
YoY Change	-21.25%	-23.29%	-3.78%
INVESTING ACTIVITIES
Capital Expenditures	-$1.800M	-$1.900M	-$5.300M
YoY Change	-51.35%	-64.15%	178.95%
Acquisitions
YoY Change
Other Investing Activities	$94.50M	$50.60M	$63.60M
YoY Change	-32.11%	-20.44%	-110.27%
Cash From Investing Activities	$92.70M	$48.70M	$58.20M
YoY Change	-31.59%	-16.32%	-109.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	148.9M	1.600M	6.200M
YoY Change	2878.0%	-74.19%	58.97%
NET CHANGE
Cash From Operating Activities	-98.60M	-52.70M	-68.70M
Cash From Investing Activities	92.70M	48.70M	58.20M
Cash From Financing Activities	148.9M	1.600M	6.200M
Net Change In Cash	143.0M	-2.400M	-4.300M
YoY Change	834.64%	-44.19%	-99.38%
FREE CASH FLOW
Cash From Operating Activities	-$98.60M	-$52.70M	-$68.70M
Capital Expenditures	-$1.800M	-$1.900M	-$5.300M
Free Cash Flow	-$96.80M	-$50.80M	-$63.40M
YoY Change	-20.33%	-19.87%	-8.78%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	City Area Code CityAreaCode	415
	dei	Local Phone Number LocalPhoneNumber	482-5300
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0000906709
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	us-gaap:AccountingStandardsUpdate201911Member
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2020-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	0-24006
	dei	Entity Registrant Name EntityRegistrantName	NEKTAR THERAPEUTICS
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	94-3134940
	dei	Entity Address Address Line1 EntityAddressAddressLine1	455 Mission Bay Boulevard South
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Francisco
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94158
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
	dei	Trading Symbol TradingSymbol	NKTR
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2020Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	179398666	shares
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55843000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	96363000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	900163000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1228499000	USD
CY2020Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	42925000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	36802000	USD
CY2020Q3	us-gaap	Inventory Net InventoryNet	12892000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	12665000	USD
CY2020Q3	nktr	Advance Payments To Contract Manufacturers AdvancePaymentsToContractManufacturers	10483000	USD
CY2019Q4	nktr	Advance Payments To Contract Manufacturers AdvancePaymentsToContractManufacturers	31834000	USD
CY2020Q3	us-gaap	Other Assets Current OtherAssetsCurrent	21550000	USD
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	15387000	USD
CY2020Q3	us-gaap	Assets Current AssetsCurrent	1043856000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	1421550000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	197715000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	279119000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	60189000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	65665000	USD
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	128985000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	134177000	USD
CY2020Q3	us-gaap	Goodwill Goodwill	76501000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	76501000	USD
CY2020Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1420000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	344000	USD
CY2020Q3	us-gaap	Assets Assets	1508666000	USD
CY2019Q4	us-gaap	Assets Assets	1977356000	USD
CY2020Q3	us-gaap	Senior Notes Current SeniorNotesCurrent	0	USD
CY2019Q4	us-gaap	Senior Notes Current SeniorNotesCurrent	252891000	USD
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	15484000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	19234000	USD
CY2020Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	29504000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11467000	USD
CY2020Q3	nktr	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	48886000	USD
CY2019Q4	nktr	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	32626000	USD
CY2020Q3	nktr	Accrued Contract Manufacturing Expense Current AccruedContractManufacturingExpenseCurrent	7141000	USD
CY2019Q4	nktr	Accrued Contract Manufacturing Expense Current AccruedContractManufacturingExpenseCurrent	7304000	USD
CY2020Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	9630000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	12338000	USD
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	15348000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	12516000	USD
CY2020Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	507000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5517000	USD
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	126500000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	353893000	USD
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	139022000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	142730000	USD
CY2020Q3	nktr	Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts	66378000	USD
CY2019Q4	nktr	Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts	72020000	USD
CY2020Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2494000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2554000	USD
CY2020Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3291000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	768000	USD
CY2020Q3	us-gaap	Liabilities Liabilities	337685000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	571965000	USD
CY2020Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q4	nktr	Preferred Stock Share Designated PreferredStockShareDesignated	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q3	nktr	Preferred Stock Share Designated PreferredStockShareDesignated	0	shares
CY2020Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-1300000	USD
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	179394000	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	176505000	shares
CY2020Q3	us-gaap	Common Stock Value CommonStockValue	18000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	17000	USD
CY2020Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	3363998000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	3271097000	USD
CY2020Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1080000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1005000	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2191955000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1864718000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	1170981000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	1405391000	USD
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1508666000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1977356000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30033000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29218000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	129453000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	80755000	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5570000	USD
CY2019Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4927000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	15154000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	15385000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	100531000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	99048000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	305954000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	324197000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26982000	USD
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23983000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	77546000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	71570000	USD
CY2020Q3	nktr	Impairment Of Equipment And Other Costs For Terminated Program ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram	0	USD
CY2019Q3	nktr	Impairment Of Equipment And Other Costs For Terminated Program ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram	0	USD
	nktr	Impairment Of Equipment And Other Costs For Terminated Program ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram	45189000	USD
	nktr	Impairment Of Equipment And Other Costs For Terminated Program ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram	0	USD
CY2020Q3	us-gaap	Costs And Expenses CostsAndExpenses	133083000	USD
CY2019Q3	us-gaap	Costs And Expenses CostsAndExpenses	127958000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	443843000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	411152000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-103050000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-98740000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-314390000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-330397000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	0	USD
CY2019Q3	us-gaap	Interest Expense InterestExpense	5425000	USD
	us-gaap	Interest Expense InterestExpense	6851000	USD
	us-gaap	Interest Expense InterestExpense	15882000	USD
CY2020Q3	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	8425000	USD
CY2019Q3	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	5813000	USD
	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	22084000	USD
	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	17853000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2910000	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	11492000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	16453000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	35964000	USD
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5515000	USD
CY2019Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	254000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-12482000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2229000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-108565000	USD
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-98486000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-326872000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-328168000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	21000	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	99000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	365000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	365000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	335000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-108586000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-98585000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-327237000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-328503000	USD
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.61
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.56
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.84
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.88
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	179090000	shares
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	175402000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	178203000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	174609000	shares
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-108586000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-98585000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-327237000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-328503000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-2144000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-261000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	423000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	6621000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	349000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-360000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-498000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-217000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1795000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-621000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-75000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	6404000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-110381000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-99206000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-327312000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-322099000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	1717575000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5463000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	25385000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-114912000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	1633511000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	7103000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	24522000	USD
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-107981000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	1557155000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5882000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	24880000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-99206000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	1488711000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	1405391000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	11347000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	24211000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-144523000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	1296426000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	7826000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	24396000	USD
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-72408000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	1256240000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1455000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	23667000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-110381000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	1170981000	USD
	us-gaap	Profit Loss ProfitLoss	-327237000	USD
	us-gaap	Profit Loss ProfitLoss	-328503000	USD
	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	28001000	USD
	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	27585000	USD
	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	22084000	USD
	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	17853000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	72274000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	74787000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	10937000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	9582000	USD
	nktr	Impairment Of Equipment From Terminated Program ImpairmentOfEquipmentFromTerminatedProgram	20351000	USD
	nktr	Impairment Of Equipment From Terminated Program ImpairmentOfEquipmentFromTerminatedProgram	0	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1150000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	9147000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6123000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2008000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	227000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2339000	USD
	nktr	Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities	-4316000	USD
	nktr	Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities	-11550000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	5588000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-18127000	USD
	nktr	Debt Investment Maturity Term DebtInvestmentMaturityTerm	P1Y
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3337000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	16109000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	20478000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	13164000	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	9340000	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	10401000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-5070000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-9465000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-214653000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-203458000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	791445000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	1028883000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	1158722000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	1122902000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	41700000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5504000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	22614000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	403473000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	71405000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	20651000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	18449000	USD
	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	250000000	USD
	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-229349000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18449000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-77000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-40520000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-113681000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	96363000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	194905000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	55843000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	81224000	USD
	us-gaap	Interest Paid Net InterestPaidNet	9742000	USD
	us-gaap	Interest Paid Net InterestPaidNet	14299000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2133000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	56025000	USD
CY2020Q3	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	1200000000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning the COVID-19 pandemic and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We consider the effects of the COVID-19 pandemic in developing our estimates.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual results could differ materially from those estimates and assumptions. As appropriate, we assess our estimates each period, update them to reflect current information and generally recognize any changes in such estimates in the period first identified.</span></div>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc2YzE3YTNiZmY2MjQ1ODY4MzM2Mjg2MDc0YzQ3NjA4L3NlYzo3NmMxN2EzYmZmNjI0NTg2ODMzNjI4NjA3NGM0NzYwOF8zNy9mcmFnOmJlNWFlODIzZjNkNjQ5OTU4MDU2YmEyNTA5YmQ2YTA1L3RleHRyZWdpb246YmU1YWU4MjNmM2Q2NDk5NTgwNTZiYTI1MDliZDZhMDVfNTQzMg_facdf9c8-a26e-4931-8e77-5a08808f543a">ASU 2019-12</span> - Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12). ASU 2019-12 created an exception to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items (for example, discontinued operations or other comprehensive income). Under the historical guidance, in this situation, an entity would record an income tax provision from other items, such as unrealized gains on available-for-sale securities reported in other comprehensive income, with an offsetting income tax benefit in continuing operations. Under ASU 2019-12, an entity would record no income tax provision. We elected to adopt ASU 2019-12 effective January 1, 2019 on a prospective basis in accordance with the guidance. Because we reported a net loss and unrealized gains on available-for-sale securities during 2019 and accordingly recorded a tax provision pursuant to the legacy guidance, we have recast such results from previously reported amounts. As a result, we eliminated the tax benefit in continuing operations and tax provision in other comprehensive income (loss). The tax effect in continuing operations was a tax benefit of $1.3 million for the nine months ended September 30, 2019, and was a tax expense of $0.2 million for the three months ended September 30, 2019.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating loss, net loss, total assets, liabilities or stockholders’ equity.</span></div>
CY2019Q3	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	200000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Concentrations</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S. and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), other contingent payments and royalties, as well as reimbursable costs from collaborative research and development agreements. As of September 30, 2020, our accounts receivable includes $13.0 million under customer contracts from our collaboration partners and $29.9 million for unbilled net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS). As of December 31, 2019, our accounts receivable included $12.8 million from customer contracts and $24.0 million for unbilled net expense reimbursements from BMS. We generally do not require collateral from our customers. We perform a regular review of our customers’ credit risk and payment histories, including payments made after period end. Historically, we have not experienced credit losses from our accounts receivable and recorded no bad debt expense for the three and nine months ended September 30, 2020 and 2019. We have not recorded a reserve for credit losses at September 30, 2020 or December 31, 2019.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industry. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, the COVID-19 pandemic may materially affect the financial conditions of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer’s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. As a result of the COVID-19 pandemic, we have begun to see an increase in credit downgrades for certain of our securities. Accordingly, if the COVID-19 pandemic or other factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.</span></div>
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55843000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	96363000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	900163000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1228499000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	197715000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	279119000	USD
CY2020Q3	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	1153721000	USD
CY2019Q4	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	1603981000	USD
	nktr	Debt Investment Maximum Maturity Period DebtInvestmentMaximumMaturityPeriod	P2Y
CY2020Q3	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	41700000	USD
CY2019Q3	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	USD
CY2020Q3	us-gaap	Interest Receivable Current InterestReceivableCurrent	5400000	USD
CY2019Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	6500000	USD
CY2020Q3	us-gaap	Cash Cash	6368000	USD
CY2019Q4	us-gaap	Cash Cash	5829000	USD
CY2020Q3	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	1153721000	USD
CY2019Q4	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	1603981000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2100000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	300000	USD
CY2020Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1387000	USD
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1673000	USD
CY2020Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	11188000	USD
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	8267000	USD
CY2020Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	317000	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2725000	USD
CY2020Q3	us-gaap	Inventory Net InventoryNet	12892000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	12665000	USD
	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	28000000.0	USD
	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	27600000	USD
	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	22100000	USD
	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	17900000	USD
	nktr	Estimated Annual Interest Rate Over Life Of Royalty Liability EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability	0.17
CY2020Q3	nktr	Estimated Annual Interest Rate Over Life Of Royalty Liability EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability	0.202
CY2020Q3	nktr	Prospective Interest Rate Percentage ProspectiveInterestRatePercentage	0.48
CY2020Q3	nktr	License Collaboration Other Revenue LicenseCollaborationOtherRevenue	1631000	USD
CY2019Q3	nktr	License Collaboration Other Revenue LicenseCollaborationOtherRevenue	3121000	USD
	nktr	License Collaboration Other Revenue LicenseCollaborationOtherRevenue	55421000	USD
	nktr	License Collaboration Other Revenue LicenseCollaborationOtherRevenue	9860000	USD
CY2020Q3	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	22700000	USD
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	109400000	USD
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	8071000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	5070000	USD
CY2020Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3001000	USD
CY2020Q3	nktr	Potential Development And Regulatory Milestones PotentialDevelopmentAndRegulatoryMilestones	1700000000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	23667000	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24880000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	72274000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	74787000	USD
CY2020Q3	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	584000	shares
CY2019Q3	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	820000	shares
	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	2889000	shares
	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	2256000	shares
CY2020Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16575000	shares
CY2019Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17163000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17499000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18012000	shares

Files In Submission

Name	View Source	Status
0000906709-20-000017-index-headers.html	Edgar Link	pending
0000906709-20-000017-index.html	Edgar Link	pending
0000906709-20-000017.txt	Edgar Link	pending
0000906709-20-000017-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nktr-20200930.htm	Edgar Link	pending
nktr-20200930.xsd	Edgar Link	pending
nktr-20200930_cal.xml	Edgar Link	unprocessable
nktr-20200930_def.xml	Edgar Link	unprocessable
nktr-20200930_htm.xml	Edgar Link	completed
nktr-20200930_lab.xml	Edgar Link	unprocessable
nktr-20200930_pre.xml	Edgar Link	unprocessable
nktr2020-09x30xexx311.htm	Edgar Link	pending
nktr2020-09x30xexx312.htm	Edgar Link	pending
nktr2020-09x30xexx321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NKTR
Nektar Therapeutics Stock $nktr

2020 Q4 Form 10-Q Financial Statement

#000090670920000017 Filed on November 06, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NKTR Nektar Therapeutics Stock $nktr

2020 Q4 Form 10-Q Financial Statement

#000090670920000017 Filed on November 06, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NKTR
Nektar Therapeutics Stock $nktr